The primary goal of this edition is to extract the relevant specialty chapters from the parent Harrison's text into a for focused study. It bridges the gap between basic science and clinical application by integrating pathophysiology directly with clinical management strategies. II. Core Clinical Sections

Digestive diseases account for a substantial proportion of outpatient visits, hospital admissions, and specialist consultations. Missteps in diagnosis or delayed recognition of conditions like ischemic colitis, early pancreatic cancer, or acute-on-chronic liver failure carry grave consequences.

Covers the "why" behind symptoms like abdominal pain, jaundice, and nausea. Disease Categories:

Comprehensive review of viral hepatitis, cirrhosis, and metabolic dysfunction-associated liver diseases. Pancreas & Neoplastic Disease:

The biologic and small-molecule landscape for Crohn’s disease and ulcerative colitis has exploded. This edition provides updated algorithms for anti-TNF agents (infliximab, adalimumab), anti-integrins (vedolizumab), anti-IL-23 agents (risankizumab, mirikizumab), and JAK inhibitors (upadacitinib). Real-world efficacy data and safety profiles are presented in easy-to-read tables.

Comprehensive updates on GERD, peptic ulcer disease, and inflammatory bowel disease (IBD).